ITEMS IN AFP WITH KEYWORD:
Chronic Obstructive Pulmonary Disease
Triple inhaled therapy, with budesonide (Pulmicort) in a dose of either 160 mcg or 320 mcg daily plus a long-acting muscarinic antagonist (LAMA) and a long-acting beta2 agonist (LABA), reduces moderate exacerbations (a need for an antibiotic or steroid for three or more days) more than either a LAMA...
Short-term antibiotic treatment and short-term systemic corticosteroids are both associated with a faster resolution of COPD symptoms and fewer treatment failures.
Jul 1, 2020 Issue
Role of Mucolytics in the Treatment of Chronic Bronchitis or COPD [Cochrane for Clinicians]
Oral mucolytic agents may reduce the number of acute exacerbations in patients with chronic bronchitis or COPD (number needed to treat [NNT] = 8 over an average of nine months; 95% CI, 7 to 10).
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by hyperinflation of the lungs, including emphysema and chronic bronchitis. Learn more about the benefits and harms of using noninvasive positive pressure ventilation for exacerbation of COPD.
What are the benefits and harms of pharmacologic and nonpharmacologic treatments for exacerbations of chronic obstructive pulmonary disease (COPD) in adults?
High-quality, office-based spirometry can be as useful and reliable as testing performed in a pulmonary function laboratory. A stepwise approach to spirometry should be used, including assessing for obstruction and reversibility, grading of severity, and referral for full pulmonary testing as indicated.
Feb 1, 2020 Issue
Antibiotics for Exacerbations of Chronic Obstructive Pulmonary Disease [Medicine by the Numbers]
Prescription of antibiotics for the treatment of chronic obstructive pulmonary disease (COPD) is controversial due to the variety of etiologies. This review examined the use of antibiotics to treat COPD in outpatient, inpatient, and ICU settings. Read more.
Revefenacin is a once-daily nebulized alternative to metered dose long-acting muscarinic antagonists for patients with moderate to severe COPD. Given its expense, complicated administration process, and lack of evidence that it improves key patient-oriented outcomes, its use should be limited to pat...
CRP guidance, regarding the likelihood that antibiotics will be helpful for patients with acute exacerbation of COPD, safely reduces antibiotic use (number needed to treat = 5).
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.